In adult patients with community-acquired pneumonia, how many days should hydrocortisone be administered as adjunctive therapy?

Hydrocortisone Duration in Community-Acquired Pneumonia

When hydrocortisone is used for severe community-acquired pneumonia, administer it for 7 days (or 4 days if clinical improvement occurs earlier), followed by tapering for a total treatment duration of 8-14 days.

Key Recommendation Based on Evidence Quality

The most recent high-quality evidence comes from the CAPE COD trial 1, which used hydrocortisone 200 mg daily for either 4 or 7 days (determined by clinical improvement), followed by tapering for a total duration of 8 or 14 days. This regimen demonstrated a significant mortality reduction in severe CAP (6.2% vs 11.9% in placebo, p=0.006).

Important Context: When to Use Corticosteroids

Corticosteroids should NOT be routinely used in most pneumonia cases. The 2019 ATS/IDSA guidelines 2 provide clear direction:

• Strong recommendation AGAINST routine use in nonsevere CAP
• Conditional recommendation AGAINST routine use in severe CAP
• Conditional recommendation AGAINST use in severe influenza pneumonia

However, the guidelines note that studies used doses "up to 240 mg of hydrocortisone equivalent per day for a maximum of 7 days" 2.

Specific Dosing Regimens from Evidence

For Severe CAP (if used):

• CAPE COD protocol 1: 200 mg/day IV for 4-7 days based on clinical improvement, then taper over total 8-14 days
• REMAP-CAP protocol 3: 50 mg IV every 6 hours (200 mg/day) for 7 days
• FDA labeling 4: Initial dose 100-500 mg, repeated every 2-6 hours as needed; high-dose therapy should not exceed 48-72 hours

Duration Considerations:

The FDA label 4 specifically states: "high dose corticosteroid therapy should be continued only until the patient's condition has stabilized, usually not beyond 48 to 72 hours." However, clinical trials in severe CAP have used 7-day courses with better outcomes 3, 1.

Critical Caveats and Pitfalls

When NOT to Use:

• Nonsevere CAP: No mortality or organ failure benefit 2
• Influenza pneumonia: May increase mortality 2, 5
• Viral pneumonia (non-COVID): Should be avoided 5

Side Effects to Monitor:

• Hyperglycemia requiring insulin therapy (most common) 2, 1
• Possible increased rehospitalization rates 2
• Secondary infections (though not significantly increased in trials) 6
• Hypernatremia if continued beyond 48-72 hours 4

Exception - Septic Shock:

The guidelines endorse Surviving Sepsis Campaign recommendations for corticosteroids in patients with CAP and refractory septic shock despite adequate fluid resuscitation and vasopressor support 2.

Reconciling Conflicting Evidence

The 2019 guidelines recommend against routine use, yet the 2023 CAPE COD trial 1 showed clear mortality benefit. This discrepancy reflects:

• Population differences: CAPE COD enrolled only ICU patients with severe CAP
• Timing: The guideline preceded the CAPE COD results
• Heterogeneity: Not all severe CAP patients benefit equally 5, 7

Recent 2025-2026 evidence 6, 8 supports corticosteroid use specifically in severe CAP with high inflammatory markers (CRP), but not in less severe disease.

Practical Algorithm

If deciding to use corticosteroids in severe CAP:

1. Confirm severe CAP (ICU admission, high inflammatory markers)
2. Exclude influenza or other viral pneumonia
3. Use hydrocortisone 200 mg/day IV (50 mg q6h)
4. Continue for 4-7 days based on clinical improvement
5. Taper over additional days for total 8-14 day course
6. Monitor glucose closely and treat hyperglycemia aggressively

Do not use in nonsevere CAP, outpatient pneumonia, or viral pneumonia (except COVID-19).